Authors
Alicia Lieberman, Ross McCauley, Maureen Ross, Philip McCarthy, Iming Cho, Simona Reed, Shih-Yao Lin, Judy Chou, Shernan G Holtan
Published in
EJHaem. Volume 7. Issue 4. Pages e70342. Epub Jul 03, 2026.
Abstract
Steroid-refractory chronic cutaneous graft-versus-host disease (GVHD) causes substantial morbidity, prolonged hospitalization, and non-relapse mortality after allogeneic hematopoietic cell transplantation. We report a young adult with multisystem chronic GVHD and recurrent life-threatening inflammatory skin flares refractory to multiple standard therapies, with cumulative inpatient care exceeding 1 year. Under an institutional review board-approved compassionate-use protocol, he received a non-cytotoxic monoclonal antibody targeting CD162 (P-selectin glycoprotein ligand-1). Treatment was associated with durable resolution of active cutaneous GVHD, corticosteroid reduction, improved mobility, and meaningful recovery in daily function and quality of life.
The author has confirmed clinical trial registration is not needed for this submission.
PMID:
42405271
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0